Company Overview of Castle Biosciences Incorporated
Castle Biosciences Incorporated, a cancer based molecular diagnostics company, designs and develops cancer molecular tests for use by licensed physicians. It offers DecisionDx-uveal melanoma (UM) test that measures the gene expression profile/molecular signature of an individual's tumor and identifies the metastasis; DecisionDX-Thymoma, an objective test that determines the molecular profile of a patient’s tumor and the metastatic risk associated with thymoma; DecisionDX- glioma-CpG island methylator phenotype (G-CIMP) profile test, a multi-methylation test that determines the G-CIMP of gliomas; and DecisionDX-GBM test, a metagene expression assay that determines the molecular signature of a...
2014 San Miguel Drive
Friendswood, TX 77546-5913
Founded in 2007
Key Executives for Castle Biosciences Incorporated
Chief Executive Officer, President and Director
Vice President of Operations
Vice President of US Sales and Marketing
Compensation as of Fiscal Year 2014.
Castle Biosciences Incorporated Key Developments
Castle Biosciences Incorporated Announces Management Appointments
Feb 24 15
Castle Biosciences Inc. announced the appointment of Mara G. Aspinall to its Board of Directors, and the addition of James L. Dunn, Jr. to its senior leadership team. Mara Aspinall most recently served as President and Chief Executive Officer of the Roche Group's Ventana Medical Systems. She previously spent 12 years with Genzyme Corporation as President of Genzyme Genetics and President of Genzyme Pharmaceuticals. She was also the Founder, CEO and Director of cancer diagnostics company On-Q-ity, and has spearheaded many initiatives to educate policymakers about diagnostics and personalized medicine. Ms. Aspinall served for 15 years on the Board of the Dana Farber Cancer Institute, currently chairs the Arizona Biosciences Board. The company also welcomed James L. Dunn, Jr. as its Chief Financial Officer. With over 20 years of public company experience, Mr. Dunn has served in both CFO and general counsel roles across various industries. He most recently served as CFO of Applied Optoelectronics Inc., and successfully managed its IPO. He began his career as a Co-Founder and CFO of Pentegra Dental Group (now iLinc) from its IPO in 1998 to its successful sale in 2008.
Castle Biosciences Inc. Announces Results from a Second Validation Study of its Proprietary Multi-Analyte Test, DecisionDx-EC
Oct 23 14
Castle Biosciences Inc. announced that results from a second validation study of its proprietary multi-analyte test, DecisionDx-EC, confirmed the test's ability to identify which esophageal cancer patients are unlikely to benefit from the standard pre-surgical treatment of chemoradiation. The results were reviewed in an oral presentation at the 11th Annual Meeting of the International Society of Gastrointestinal Oncology in Arlington, Virginia. The results suggest that up to 30% of esophageal cancer patients may not benefit from the highly toxic, pre-surgical chemoradiation therapy (CTRT), and instead could have the option of moving directly to surgery and to other treatment options. The DecisionDx-EC test analyzes the localization of three protein biomarkers, NF-kB, Gli1, and SHH, to classify tumors as either responsive to (non-exCTRT) or resistant to CTRT (exCTRT). Testing was performed on formalin-fixed paraffin-embedded esophageal cancer tissue. In this second, multi-center validation study involving 64 patient cases, 67% of whom had been treated with a regimen that included 5-fluorouracil (5FU), researchers reported a 95% specificity, with positive (PPV) and negative (NPV) predictive values of 88% and 83%, respectively. These results confirm a similar analysis of an earlier validation study involving 167 patient cases, all of whom underwent a chemoradiation regimen involving 5FU plus platinum/taxanes. This study showed a specificity of 90% and positive (PPV) and negative (NPV) predictive values of 64% and 98%, respectively. The company also presented data from a parallel study of a gene expression profile (GEP) test in development for esophageal cancer. The study assessed the ability of two preliminary gene signatures to predict responsiveness to chemoradiation therapy in tumor samples from 16 patients. The results from this initial study showed that the GEP test predicted treatment response with high accuracy and specificity of 100% and 100%, respectively. The company plans to further evaluate the GEP test in esophageal and rectal cancer.
Castle Biosciences Incorporated Announces the Completion of an $11.8 Million Financing; Garheng Kong Joins as Board of Directors
Aug 13 14
Castle Biosciences Incorporated announced the completion of an $11.8 million financing. The round was led by new investor HealthQuest Capital, with participation by Castle Biosciences' current investors including Mountain Group Capital and Affiliates, Longfellow Venture Partners and others. The funds will be used to expand clinical availability of Castle Biosciences' portfolio of practice-changing cancer diagnostic tests, including DecisionDx-Melanoma, its test to determine metastatic risk in patients with melanoma.
In conjunction with this financing, Garheng Kong, M.D., Ph.D., Managing Partner of HealthQuest Capital, will join Castle Biosciences' Board of Directors.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 11, 2014
April 22, 2014